Cite
HARVARD Citation
Keystone, E. et al. (n.d.). OP0086 The fully human anti-tnf monoclonal antibody, adalimumab (d2e7), dose ranging study: the 24-week clinical results in patients with active ra on methotrexate therapy (the armada trial). Annals of the rheumatic diseases. p. A481. [Online].